Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 13/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.54 |
| ▸ | KDR | P35968 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13324662 | 1.00 | FLT3 (0.69) | FLT3MEN1KMT2ARPS6KA3KDR | |
| SCHEMBL3283974 | 1.00 | FLT3 (0.69) | FLT3MEN1KMT2ARPS6KA3KDR | |
| SCHEMBL3284964 | 0.89 | FLT3 (0.76) | FLT3MEN1KMT2ARPS6KA3KDR | |
| SCHEMBL3284971 | 0.89 | FLT3 (0.76) | FLT3MEN1KMT2ARPS6KA3KDR | |
| SCHEMBL13324656 | 0.89 | TDP1 (0.56) | FLT3MEN1KMT2ARPS6KA3NPC1 | |
| SCHEMBL3287008 | 0.89 | TDP1 (0.56) | FLT3MEN1KMT2ARPS6KA3NPC1 | |
| SCHEMBL3287012 | 0.89 | TDP1 (0.56) | FLT3MEN1KMT2ARPS6KA3NPC1 | |
| SCHEMBL3285328 | 0.83 | FLT3 (0.60) | FLT3MEN1KMT2ARPS6KA3KDR | |
| SCHEMBL13324658 | 0.83 | FLT3 (0.60) | FLT3MEN1KMT2ARPS6KA3KDR | |
| SCHEMBL3285330 | 0.83 | FLT3 (0.60) | FLT3MEN1KMT2ARPS6KA3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7714146-B2 | Azulene-oxindole compounds as multiple-kinase inhibitors and useful as anticancer agents | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2010-05-11 | — | — | US | disclosed |
| US-7714146-B2 | Azulene-oxindole compounds as multiple-kinase inhibitors and useful as anticancer agents | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2010-05-11 | — | — | US | disclosed |
| US-20080125590-A1 | Azulene compounds | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2008-05-29 | — | — | US | disclosed |
| US-20080125590-A1 | Azulene compounds | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2008-05-29 | — | — | US | disclosed |
| EP-1918277-A2 | Azulene compounds | Industrial Technology Research Institute (TW) | 2008-05-07 | — | — | EP | disclosed |
| EP-1918277-A2 | Azulene compounds | Industrial Technology Research Institute (TW) | 2008-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125590-A1 | Azulene compounds | AZI2, PRMT5, BRCA1 | FLT3 796/4885MEN1 13/4885KMT2A 2426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.